Cohance Lifesciences announces leadership changes, appoints new whole-time director

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, announced the resignation of Dr. V Prasada Raju as managing director and director, effective close of business hours on October 28, 2025. The board recorded its appreciation for Dr. Raju’s contributions.

Simultaneously, Himanshu Agarwal, currently chief financial officer, has been approved as an additional director, whole-time director, and chief financial officer for five years, starting October 29, 2025, pending shareholder approval. Agarwal is not related to existing directors or key managerial personnel.

The company will host a conference call today, October 28, 2025, at 06:30 p.m. IST, to provide updates on these directorial changes. Investors and analysts can access the call via primary numbers +91 22 6280 1141 or +91 22 7115 8042, or through various international toll-free numbers. An audio recording will be available on the company’s website following the event.

Additionally, Cohance Lifesciences has revised its authorized key managerial personnel. The updated list includes Vivek Sharma as executive chairman, Himanshu Agarwal as whole-time director and chief financial officer, and Kundan Kumar Jha as company secretary, compliance officer, and head-legal. These changes will be effective from October 29, 2025.